Depomed Inc (NASDAQ:DEPO) shares traded 3.99% up during most recent session to reach at the closing price of $6.26. The stock exchanged hands 2.9 Million shares versus average trading capacity of 1.84 Million shares, yielding a market cap of $405.84 Million. Wall Street analysts covering the stock are projecting that the stock will reach $11.13 within the next 52-weeks. The mean target projections are based on 8 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Depomed Inc (NASDAQ:DEPO) high price target of $22 and with a conservative view have low price target of $5.
Morgan Stanley “Downgrades” Depomed Inc (NASDAQ:DEPO) in a research note issued to investors on 8/08/17 to Underweight with price target of $0.
Additionally on 8/08/17 Janney Capital “Downgrades” Depomed Inc (NASDAQ:DEPO) to Neutral setting price target at $0 and on 5/10/17 PiperJaffray “Upgrades” the stock to Neutral at $0. Furthermore on 2/14/17 Mizuho “Downgrades” the stock to Neutral at $17.
On the other hand the company has Relative Strength Index (RSI 14) of 18.08 along with Average True Range (ATR 14) of 0.57, Consequently Depomed Inc (NASDAQ:DEPO)’s weekly and monthly volatility is 9.80%, 5.47% respectively. The company’s beta value is at 1.17.
In terms of Buy, Sell or Hold recommendations, Depomed Inc (NASDAQ:DEPO) has analysts’ mean recommendation of 2.5. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
According to analysts Depomed Inc (NASDAQ:DEPO)’s minimum EPS for the current quarter is at $-0.14 and can go high up to $0.21. The consensus mean EPS for the current quarter is at $0.12 derived from a total of 7 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.17 earnings per share for the same quarter during last year.
Previously Depomed Inc (NASDAQ:DEPO) reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $-0.01. The company posted an earnings surprise of -11.1%.
While considering growth estimates of the company, it has next quarter growth estimates of -30% whereas during current quarter it has -29.4% estimations over growth, comparing to the estimations of -27.1% during current year and 54.9% for next year. Past 5 years growth of Depomed Inc (NASDAQ:DEPO) observed at 38.67%, looking forward for the next 5 years it has a strong prediction of 25% over growth.
Depomed Inc (NASDAQ:DEPO)’s revenue estimates for the current quarter are $104.53 Million according to 6 number of analysts, for the current quarter the company has high revenue estimates of $108.98 Million in contradiction of low revenue estimates of $100.25 Million. For the current year the company’s revenue estimates are $410.09 Million compared to low analyst estimates of $402.9 Million and high estimates of $418.65 Million according to 6 number of analysts.
Currently Depomed Inc (NASDAQ:DEPO)’s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 94.3%. However the six-month change in the insider ownership was recorded -82.06%, as well as three-month change in the institutional ownership was recorded 0.58%.
Depomed Inc (NASDAQ:DEPO) 52-week high price stands at $27.02 and low price stands at $5.95, its price distance from 52-week high is -76.83% while its distance from 52-week low price is 5.21%. The stock hit its 52-week high on 09/30/16, and 52-week low on 08/09/17.
Depomed Inc (NASDAQ:DEPO)’s trailing twelve month revenues are $441.6 Million, whereas its price to sales ratio for the same period is 0.92. Its book value per share for the most recent quarter is $3.71 while its price to book ratio for the same period is 1.69, as for as the company’s cash per share for the most recent quarter is $3, however its price to cash per share ratio for the same period is 2.09. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.